Archived Content

The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.

Vaccines, Blood & Biologics

RAC Letter - MebHibrix

 

Our STN: BL 125363/0
 
GlaxoSmithKline Biologicals
Attention:  Jody Gould, Ph.D.
2301 Renaissance Blvd.
P.O. Box 61540
King of Prussia, PA 19406
 
Dear Dr. Gould:
 
We have received your April 15, 2011, resubmission to your biologics license application for Meningococcal Groups C and Y and Haemophilus b Tetanus Toxoid Conjugate Vaccine, for active immunization of infants and toddlers 6 weeks through 15 months of age for the prevention of invasive diseases caused by Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y on April 15, 2011.
 
We consider this a complete, Class 2 response to our action letter. Therefore, the user fee goal date is October 15, 2011.
 
If you have any questions, please contact the Regulatory Project Manager, CDR David Staten, at (301) 796-2640.
 
Sincerely yours,
 
 /s/
 
Wellington Sun, M.D.
Director
Division of Vaccines and
Related Product Applications
Office of Vaccines
Research and Review
Center for Biologics
Evaluation and Research
 

 

Page Last Updated: 07/15/2012
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English